Coronary stent choice in patients with acute myocardial infarction

Current Cardiology Reports

Volumn 14, Issue 4, 2012, Pages 477-485

  Stefanini, Giulio G ^a   Windecker, Stephan ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Acute myocardial infarction; Bare metal stents; Biodegradable polymer; Biolimus; Coronary artery stents; Drug eluting stents; Everolimus; Newer generation drug eluting stents; Primary percutaneous coronary intervention; STEMI; Stent thrombosis; Zotarolimus

Indexed keywords

PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

ACUTE HEART INFARCTION; ARTICLE; BARE METAL STENT; CLINICAL EFFECTIVENESS; CORONARY STENT; DRUG ELUTING STENT; HUMAN; INTERMETHOD COMPARISON; NEOINTIMA; PATIENT SAFETY; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; EVIDENCE-BASED MEDICINE; HUMANS; MYOCARDIAL INFARCTION; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STENTS;

EID: 84865590701     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-012-0281-y     Document Type: Article

References (47)

1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet. 2003;361:13-20. (Pubitemid 36050955)
2. Widimsky P, Wijns W, Fajadet J, et al. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: Description of the current situation in 30 countries. Eur Heart J. 2010;31:943-57.
3. De Luca G, Suryapranata H, Stone GW, et al. Coronary stenting versus balloon angioplasty for acute myocardial infarction: A meta-regression analysis of randomized trials. Int J Cardiol. 2008;126:37-44. (Pubitemid 351509626)
4. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med. 2006;355:1093-104. (Pubitemid 44394916)
5. Laarman GJ, Suttorp MJ, DirksenMT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med. 2006;355:1105-13. (Pubitemid 44394917)
6. Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med. 2009;360:1946-59. This is the largest available randomized trial comparing DES with BMS in patients with acute MI.
7. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation. 2007;115:2435-41. (Pubitemid 46717966)
8. Cook S, Wenaweser P, Togni M, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007;115:2426-34. (Pubitemid 46717965)
9. Nakazawa G, Finn AV, Joner M, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: An autopsy study. Circulation. 2008;118:1138-45.
10. Cook S, Ladich E, Nakazawa G, et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation. 2009;120:391-9.
11. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials. A case for standardized definitions. Circulation. 2007;115:2344-51. (Pubitemid 46685903)
12. Curfman GD, Morrissey S, Jarcho JA, Drazen JM. Drug-eluting coronary stents-promise and uncertainty. N Engl J Med. 2007;356:1059-60.
13. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-80. (Pubitemid 34586912)
14. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxeleluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-31. (Pubitemid 38067635)
15. Leibundgut G, Nietlispach F, Pittl U, Brunner-La Rocca H, Kaiser CA, Pfisterer ME. Stent thrombosis up to 3 years after stenting for ST-segment elevation myocardial infarction versus for stable angina -comparison of the effects of drug-eluting versus bare-metal stents. Am Heart J. 2009;158:271-6.
16. de la Llera LS Diaz, Ballesteros S, Nevado J, et al. Sirolimuseluting stents compared with standard stents in the treatment of patient with primary angioplasty. Am Heart J. 2007;154:164.e1-e6.
17. Kaltoft A, Kelbaek H, Thuesen L, et al. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) trial. J Am Coll Cardiol. 2010;56:641-5.
18. Sanchez PL, Gimeno F, Ancillo P, et al. Role of the paclitaxeleluting stent and tirofiban in patients with st-elevation myocardial infarction undergoing postfibrinolysis angioplasty the GRACIA-3 randomized clinical trial. Circ: Cardiovasc Interv. 2010;3:297-307.
19. Tierala I, Syvanne M, Kupari M. Comparison of paclitaxel-eluting with bare metal stents in acute myocardial infarction: The HAAMUSTENT study. Presented at the Transcatheter Cardiovascular Therapeutics meeting (TCT 2006), Washington, DC, October 2006.
20. van der Hoeven BL, Liem SS, Jukema JW, et al. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome. Results from the MISSION! intervention study. J Am Coll Cardiol. 2008;51:618-26. (Pubitemid 351186867)
21. Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: The MULTISTRATEGY randomized trial. JAMA: J Am Med Assoc. 2008;22:1788-99. (Pubitemid 351549970)
22. Pasceri V, Granatelli C, Pristipino C, et al. A randomized trial of a rapamycin-eluting stent in acute myocardial infarction: Preliminary results. Am J Cardiol. 2003;92(Suppl 6A):1L.
23. Di Lorenzo E, De Luca G, Sauro R, et al. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) randomized trial. JACC: Cardiovasc Interv. 2009;2:515-23.
24. Chechi T, Vittori G, Biondi Zoccai GGL, et al. Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (SELECTION). J Interv Cardiol. 2007;20:282-91. (Pubitemid 47228553)
25. Menichelli M, Parma A, Pucci E, et al. Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol. 2007;49:1924-30. (Pubitemid 46694284)
26. Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimuseluting stent vs abciximab and bare-metal stent for acute myocardial infarction: A randomized trial. JAMA. 2005;293:2109-17. (Pubitemid 40617063)
27. •• Kalesan B, Pilgrim T, Heinimann K, et al. Comparison of drugeluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33:977-87. This recent meta-analysis summarizes the accumulated randomized evidence with early-generation DES in acute MI, pointing out a higher risk of very late ST with early-generation DES compared to BMS.
28. • Guo N, Maehara A, Mintz GS, et al. Incidence, mechanisms, predictors, and clinical impact of acute and late stent malapposition after primary intervention in patients with acutemyocardial infarction: An intravascular ultrasound substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. Circulation. 2010;122:1077-84. An IVUS substudy of the HORIZONS-AMI trial showing a higher rate of LASM after PES compared to BMS implantation.
29. •Guagliumi G, Costa MA, Sirbu V, et al. Strut coverage and late malapposition with paclitaxel-eluting stents compared with bare metal stents in acute myocardial infarction: Optical coherence tomography substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. Circulation. 2011;123:274-81. An OCT substudy of the HORIZONS-AMI trial showing a higher rate of uncovered and malapposed stent struts 13 months after PES implantation compared with BMS implantation.
30. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362:1663-74.
31. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimuseluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363:136-46.
32. Leon MB, Mauri L, Popma JJ, et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol. 2010;55:543-54.
33. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): A randomised non-inferiority trial. Lancet. 2008;372:1163-73.
34. Byrne RA, Kastrati A, Kufner S, et al. Randomized, noninferiority trial of three limus agent-eluting stents with different polymer coatings: The Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) trial. Eur Heart J. 2009;30:2441-9.
35. Lee CW, Park DW, Lee SH, et al. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. Am J Cardiol. 2009;104:1370-6.
36. Kang WC, Ahn T, Lee K, et al. Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: Results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial. EuroIntervention. 2011;7:936-43.
37. •• Sabaté M. A clinical evaluation of Xience-V stent in acute myocardial infarction: The EXAMINATION trial. Presentation at Congress of European Society of Cardiology; Aug 27-31, 2011; Paris, France. This is the largest available trial comparing a newer-generation DES with BMS in patients with acute MI.
38. Hofma SH. XAMI: Randomized multi-center trial comparing first generation Sirolimus-eluting with second generation Everolimuseluting stents in primary PCI for AMI. Presented at EuroPCR 2011. May 17-20, 2011. Paris, France.
39. Kaiser C, Galatius S, Erne P, et al. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med. 2010;363:2310-9.
40. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): A randomised trial. Lancet. 2010;375:201-9.
41. Rasmussen K, Maeng M, Kaltoft A, et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): A randomised controlled superiority trial. Lancet. 2010;375:1090-9.
42. Kedhi E, Gomes M, Joesoef KS, et al. Everolimus-eluting stents and paclitaxel-eluting stents in patients presenting withmyocardial infarction: Insights from the two year results of the COMPARE prospective randomised controlled trial. EuroIntervention. 2012;7:1376-85.
43. Windecker S. Clinical and angiographic outcomes in patients with acute myocardial infarction from the RESOLUTE All Comers Open Label Randomized Trial -RESOLUTE-AMI. Presented at the Transcatheter Cardiovascular Therapeutics meeting (TCT 2010), Washington, DC, September 2010.
44. Stefanini GG, Kalesan B, Serruys PW, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised noninferiority trial. Lancet. 2011;378:1940-8.
45. Stefanini GG. Long-term outcomes of biodegradable polymer drug-eluting stents versus durable polymer sirolimus-eluting stents in patients with acute myocardial infarction: A pooled analysis of individual patient data from the ISAR-TEST 4 and LEADERS randomized trials. Presented at the ACC/ACC.i2 Scientific Session 2012. Chicago, 24-27 March 2012.
46. Pedersen S. Improved two-year outcomes of STEMI patients treated with drug-eluting compared with bare-metal stents. Experiences from the randomized BASKET-PROVE trial. Presented at the European Society of Cardiology Congress (ESC 2011). August 2011, Paris, France.
47. Palmerini T, Biondi-Zoccai G, Riva DD, et al. Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis. Lancet. 2012; published ahead of print on 23 March 2012.